| ¿µ¹® | rheumatoid factor | ÇÑ±Û | ·ù¸¶Æ¼½º ÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | IgGÀÇ FcºÎÀ§¿¡ ÀÖ´Â Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼ ÀüÇüÀûÀÎ ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) ȯÀÚÀÇ 80%¿¡¼ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀÚ´Â IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁÖ·Î IgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù |
||
| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| FECU | factor [VIII] correctional unit |
| VIIIc | factor VIII clotting activity |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| VIII:C | VIII coagulant activity |
|---|---|
| VIII C:Ag | VIII coagulant antigen |
| FVIII:C | Factor VIII Coagulant Activity |
| FVIII:C | Factor VIII: coagulant |
| VIII-VWF | VIII-von Willebrand factor |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| serum factor VIII antigen | A test used to measure the activity of a blood clotting factor VIII (Von Willebrand factor). This test is usually used to monitor treatment of haemophilia. Abnormally low factor VIII assays may be seen in the following conditions: congenital deficiency of factor VIII (haemophilia), DIC and secondary fibrinolysis. This test may also be performed in the evaluation of Von Willebrand's disease. (27 Sep 1997) |
|---|---|
| factor viii | A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs. (12 Dec 1998) |
| factor viii assay | A test used to measure the activity of a blood clotting factor VIII (Von Willebrand factor). This test is usually used to monitor treatment of haemophilia. Abnormally low factor VIII assays may be seen in the following conditions: congenital deficiency of factor VIII (haemophilia), DIC and secondary fibrinolysis. This test may also be performed in the evaluation of Von Willebrand's disease. (27 Sep 1997) |
| factor viii deficiency | A sex-linked genetic disease affecting males that results from a deficiency of clotting factor VIII, a protein factor that is required for normal blood coagulation. Symptoms include easy bruising, bleeding gums, nosebleeds and bleeding into muscle tissue (haematoma) or a joint space (haemarthrosis). Treatment includes the infusion of factor VIII concentrate intravenously to restore this essential factor and normalize blood coagulation. Inheritance: sex-linked. (27 Sep 1997) |
| anti-coagulant agents | Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels. (12 Dec 1998) |
| medication, anti-coagulant | Blood thinners. Drugs, like heparin and warfarin, used as blood-thinners to prevent blood clots and to maintain open blood vessels. (12 Dec 1998) |
| coagulant | 1. An agent that causes, stimulates, or accelerates coagulation, especially with reference to blood. Synonym: coagulative. (05 Mar 2000) |
| glycogen storage disease type VIII | <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon. Inheritance: X-linked recessive (12 Dec 1998) |
| cochlear root of VIII nerve | <anatomy, nerve> One of the components of the vestibulocochlear nerve; it is made up of the central processes of the bipolar neurons which compose the spiral (cochlear) ganglion in the spiral canal of the modiolus of the bony cochlea; the cochlear root enters the cranial cavity by passing in fascicles through the spiral foraminous tract at the bottom of the internal auditory meatus; it enters the brainstem through the pontomedullary groove, closely adhering to the caudoventral aspect of the vestibular root, and distributes its fibres to the ventral and dorsal cochlear nuclei in the floor of the lateral recess of the fourth ventricle. Synonym: radix cochlearis, cochlear root of vestibulocochlear nerve, inferior root of vestibulocochlear nerve, radix inferior nervi vestibulocochlearis. (05 Mar 2000) |
| cranial nerve VIII | <anatomy, nerve> The vestibulocochlear nerve is responsible for the sense of hearing and balance (body position sense). Lesions of the eighth nerve can result in deafness, tinnitus, dizziness, vertigo and vomiting. Synonym: cranial nerve VIII. (27 Sep 1997) |
| type VIII mucopolysaccharidosis | <syndrome> An autosomal recessive disorder due to a deficiency of a beta-glucuronidase; defective lysosomal degradation of dermatan sulfate, heparan sulfate, and chondroitin sulfate; cellular function disrupted in most tissues. Synonym: type VII mucopolysaccharidosis, type VIII mucopolysaccharidosis. (05 Mar 2000) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
| adrenal weight factor | A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex. (05 Mar 2000) |
| adrenocorticotropic releasing factor | Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|